FOXP3 and acute myeloid leukemia: We found that the proportion of Foxp3+ γδ T cells was higher in both de novo AML and AML-NR patients compared with AML-CR patients and HIs (NR vs. CR, P ≤ 0.001; NR vs. HI, P ≤ 0.001; de novo vs. CR, P ≤ 0.001; de novo vs. HI, P ≤ 0.001) with the observed pattern AML-NR (median: 6.81%, range: 3.75%-12.80%) > de novo AML (median: 4.47%, range: 1.33%-28.20%) > HIs (median: 2.13%, range: 0.18%-6.12%) > AML-CR (median: 1.65%, range: 1.02%-7.74%) groups (Figures 1(a)–1(c)).